National Institute of Health, Ministry of Health, Maputo, Mozambique.
J Bras Pneumol. 2014 Mar-Apr;40(2):142-7. doi: 10.1590/s1806-37132014000200007.
To determine the drug resistance profile of Mycobacterium tuberculosis in Mozambique.
We analyzed secondary data from the National Tuberculosis Referral Laboratory, in the city of Maputo, Mozambique, and from the Beira Regional Tuberculosis Referral Laboratory, in the city of Beira, Mozambique. The data were based on culture-positive samples submitted to first-line drug susceptibility testing (DST) between January and December of 2011. We attempted to determine whether the frequency of DST positivity was associated with patient type or provenance.
During the study period, 641 strains were isolated in culture and submitted to DST. We found that 374 (58.3%) were resistant to at least one antituberculosis drug and 280 (43.7%) were resistant to multiple antituberculosis drugs. Of the 280 multidrug-resistant tuberculosis cases, 184 (65.7%) were in previously treated patients, most of whom were from southern Mozambique. Two (0.71%) of the cases of multidrug-resistant tuberculosis were confirmed to be cases of extensively drug-resistant tuberculosis. Multidrug-resistant tuberculosis was most common in males, particularly those in the 21-40 year age bracket.
M. tuberculosis resistance to antituberculosis drugs is high in Mozambique, especially in previously treated patients. The frequency of M. tuberculosis strains that were resistant to isoniazid, rifampin, and streptomycin in combination was found to be high, particularly in samples from previously treated patients.
确定莫桑比克结核分枝杆菌的耐药谱。
我们分析了莫桑比克马普托市国家结核病参考实验室和贝拉市贝拉地区结核病参考实验室的二级数据。这些数据基于 2011 年 1 月至 12 月间提交的一线药物敏感性试验(DST)培养阳性样本。我们试图确定 DST 阳性率是否与患者类型或来源有关。
在研究期间,共分离出 641 株培养阳性的结核分枝杆菌,并进行了 DST。我们发现,374 株(58.3%)至少对一种抗结核药物耐药,280 株(43.7%)对多种抗结核药物耐药。在 280 例耐多药结核病病例中,184 例(65.7%)为既往治疗患者,其中大部分来自莫桑比克南部。2 例(0.71%)耐多药结核病病例确诊为广泛耐药结核病病例。耐多药结核病在男性中更为常见,特别是 21-40 岁年龄段的男性。
莫桑比克结核分枝杆菌对抗结核药物的耐药率较高,尤其是在既往治疗患者中。耐异烟肼、利福平、链霉素联合用药的结核分枝杆菌菌株频率较高,特别是在既往治疗患者的样本中。